Capecchi
Barbara Capecchi, Siena IT
Patent application number | Description | Published |
---|---|---|
20080260769 | Polypeptides for Oligomeric Assembly of Antigens - A system for expressing antigenic polypeptides in oligomeric form fuses the antigenic polypeptide to an oligomerisation polypeptide such that the oligomerisation polypeptide can interact with other oligomerisation polypeptides and bring multiple copies of the antigenic polypeptide into close proximity in the form of an oligomer. Expressing the polypeptides in oligomeric form in this way can improve their immunogenicity compared to a monomeric form. | 10-23-2008 |
20100183653 | Fusion Proteins Comprising CD4 Minimal Modules and Methods of Use Thereof - Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided. | 07-22-2010 |
20120177657 | FUSION PROTEINS COMPRISING CD4 MINIMAL MODULES AND METHODS OF USE THEREOF - Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided. | 07-12-2012 |
Barbara Capecchi, Pisa IT
Patent application number | Description | Published |
---|---|---|
20090176699 | Inhibitors Based on Fusion, Hr1 and Hr2 Sequences in Bacterial Adhesin - A known surface adhesin (NadA) in | 07-09-2009 |
John T. Capecchi, Oakdale, MN US
Patent application number | Description | Published |
---|---|---|
20080267885 | Medicinal Compositions and Method for the Preparation Thereof - Methods for the manufacture of medicinal compositions are described. A method for the manufacture of a medicinal composition according to the invention comprises: (a) Providing a biocompatible polymer of the general formula —[O—R | 10-30-2008 |
20090123391 | Novel Formulations - A pharmaceutical aerosol formulation includes a therapeutically effective amount of particulate medicament of formula (I) or a solvate thereof, a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof, and a biocompatible polymer comprising one or more compounds of formula (II) | 05-14-2009 |
20130303615 | ANTIMICROBIAL COMPOSITIONS AND METHODS - Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including, in particular, an antimicrobial lipid component, such as a fatty acid ester, fatty ether, or alkoxide derivative thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses). | 11-14-2013 |
Mario R. Capecchi, Salt Lake City, UT US
Patent application number | Description | Published |
---|---|---|
20100178696 | IN VIVO GENOME-WIDE MUTAGENESIS - Disclosed herein are compositions and methods for deleting or duplicating DNA in a mammalian genome. Also disclosed are compositions and methods for generating a random genome-wide chromosome rearrangement. Also disclosed are compositions and methods for streamlined construction of gene targeting vectors. | 07-15-2010 |
20110061116 | Animal Model of Synovial Sarcoma - Synovial sarcoma is an aggressive soft-tissue malignancy. Disclosed herein is an animal model of synovial sarcoma wherein one or more myogenic cells of the animal express recombinant SYT-SSX fusion polypeptide. Using this model, myoblasts were identified as a source of synovial sarcoma. Remarkably, within the skeletal muscle lineage, while expression of the oncoprotein in immature myoblasts leads to induction of synovial sarcoma with 100% penetrance, its expression in more differentiated cells induces myopathy without tumor induction. In addition, early widespread expression of the disclosed fusion protein disrupts normal embryogenesis, causing lethality. | 03-10-2011 |